New Coronavirus Infection Treatment Atetevir Tablets/Ritonavir Tablets Combo Package Launched

On November 24th, the State Drug Administration conditionally approved the official listing of Atetevir Tablets/Ritonavir Tablets Combination Package (trade name: Taizhongding®), a Class 1 innovative drug declared by Fujian Guangsheng Zhonglin Biotechnology Co. Taizhongding® is an oral small molecule neocoronavirus infection therapeutic agent for the treatment of adult patients with mild to moderate novel coronavirus infection (COVID-19). Patients should use the drug under the supervision of a physician and in strict accordance with the instructions.

Atenadine®, also known as "T" drug, is an innovative anti-coronavirus drug with global independent intellectual property rights, which is a broad-spectrum anti-coronavirus oral small molecule 3CL protease inhibitor. The recommended dosage is atetevir 0.15g (0.15gx1 tablet) in combination with ritonavir 0.1g (0.1gx1 tablet), administered orally twice daily for 5 days.

At present, the main anti-neocoronavirus potent drugs on the market are: RdRp inhibitors, 3CL protease inhibitors. Among them, 3CL protease inhibitors are the mainstream new coronavirus treatment drugs in the market. Tai Zhong Ding® (T drug) and Pfizer Paxlovid (P drug) are the same 3CL target. By acting on the 3CL protease of the new coronavirus, it inhibits the cleavage of the viral polyprotein precursor, thus blocking viral replication and achieving anti-neocoronavirus effects. Compared with similar anti-coronaviral oral drugs, Taizolidin® is a more effective anti-coronaviral drug with a lower daily dosage. The lower dosage of the drug can ensure the safety under the premise of viral suppression. The formal approval of Taizhongding® will bring a new treatment option to Chinese patients.